Canagliflozin might act as a dual acetylcholinesterase and SGLT2i [55], supporting a dual role for SGLT2i at the central level [56, 57] and opening an interesting venue, since acetylcholinesterase inhibitors, and NMDA receptor antagonist memantine, are the only FDA-approved options to treat AD. Here, ACHE is linked to Alzheimer disease.